期刊文献+

EGFR和K-ras在结直肠癌中的表达及其临床意义 被引量:6

Expression and clinical significance of EGFR and K-ras in colorectal cancer
原文传递
导出
摘要 【目的】检测结直肠癌中表皮生长因子受体(epidermal growth factor receptor,EGFR)和K-ras蛋白的表达情况,分析其在结直肠癌组织中表达与临床病理特征之间的关系。【方法】应用免疫组化SP法检测80例原发性结直肠癌及其相应的癌旁组织中EGFR和K-ras蛋白的表达情况。【结果】EGFR、K-ras蛋白在结直肠癌组织中的阳性表达显著高于其在癌旁组织中的表达(P<0.01)。EGFR蛋白的表达与肿瘤病理分化程度、浸润深度以及肿瘤Dukes分期、有无淋巴转移有关,Dukes分期越晚(χ2=8.935,P=0.030),分化程度越低(χ2=11.757,P=0.001),浸润深度越深(χ2=6.888,P=0.009)及有淋巴结转移者(χ2=10.889,P=0.001),其表达越高,而与患者年龄、性别、肿瘤大小、肿瘤部位无关(P>0.05);K-ras蛋白仅与肿瘤的病理分化程度有关,分化程度越低(χ2=9.528,P=0.001),其阳性表达越多。结直肠癌组织中EGFR和K-ras蛋白的共表达呈正相关性(r=0.327,P=0.002)。【结论】EGFR和K-ras在结直肠癌中存在共表达现象,二者的高表达可能促进结直肠癌的发生、发展,检测二者可辅助判断患者的预后和转移情况以及指导临床治疗。 【Objective】To analysis the expression of epidermal growth factor receptor(EGFR) and K-ras protein in colorectal cancer and its possible relationship with its expression with the clinicopathological characteristics of colorectal cancer.【Methods】The expression of EGFR and K-ras protein were examined in 80 patients with primary colorectal cancer and adjacent normal tissues by immunohistochemical SP technique.【Results】The positive expression of EGFR,K-ras protein in colorectal cancer tissues was significantly higher than its expression in adjacent normal tissues(P 0.01).EGFR protein expression of do related to the tumor histological differentiation,depth of invasion,Dukes stage tumors and lymph node metastasis.When the Dukes stage later(χ2 = 8.935,P = 0.030),the lower the degree of differentiation(χ2= 11.757,P = 0.001),the deeper the depth of invasion(χ2= 6.888,P = 0.009) and lymph node metastasis(χ2= 10.889,P = 0.001),the higher expression of EGFR protein,but has nothing to do with the patient's age,gender,tumor size,tumor site(P 0.05).K-ras protein is only related to pathological differentiation of the tumor,the lower the degree of differentiation,the more positive expression.EGFR and K-ras protein expression was positively correlated with colorectal cancer tissues(χ2= 9.528,P = 0.001).【Conclusion】EGFR and K-ras co-express in colorectal cancer.Their high expression may contribute to the occurrence and development of colorectal cancer.Testing them may help to determine the prognosis and metastasis,guide clinical treatment.
出处 《武警后勤学院学报(医学版)》 CAS 2013年第5期345-347,359,F0003,共5页 Journal of Logistics University of PAP(Medical Sciences)
基金 国家自然科学基金面上项目(30871207) 安徽省科技厅重点科研计划项目(7020304101) 安徽省教育厅重点科研项目(KJ2008A154)
关键词 表皮生长因子受体 K-RAS 结直肠肿瘤 免疫组织化学 Epidermal growth factor receptor EGFR K-ras Colorectal tumors Immunohistochemistry
  • 相关文献

参考文献14

  • 1Weitz J,Koch M,Debus J. Colorectal cancer[J].The Lancet,2005,(9454):153-165.doi:10.1016/S0140-6736(05)17706-X.
  • 2林武华,孙念绪.散发性结直肠癌与微卫星不稳定性的关系[J].武警医学院学报,2003,12(3):231-233. 被引量:2
  • 3茆家定,钱海鑫,吴佩,黄剑雄,武健.ERK-MAPK信号转导通路在胃泌素促进人结直肠癌细胞增殖中的作用及其机制[J].中华消化外科杂志,2013,12(2):139-144. 被引量:11
  • 4Lievre A,Bachet JB,Le Corre D. K-Ras mutation status is predictive of response to cetuximab therapy in colorectal cancer[J].Cancer Research,2006,(08):3992-3995.
  • 5Khamvata-Ford S,Garrett CR,Meropol NJ. Expression of epiregulin and amphiregulin and K-Ras mutation status predict disease control in metastatic colorectal Cancer patients treated with cetuximab[J].Journal of Clinical Oncology,2007,(22):3230-3237.
  • 6Jonker DJ,O'Callaghan C J,Karapetis CS. Cetuximab for the treatment of colorectal cancer[J].New England Journal of Medicine,2007,(20):2040-2048.
  • 7Van Cutseme,Lang I,Dhaens G. K-RAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetux-imab:the CRYTAL experience[J].Journal of Clinical Oncology,2008,(Supp1):a2.
  • 8梁晚平,王金科,薄爱华,白利娜,孙丰梅,张晓丽.EGFR在胃肠良恶性病变表达的临床意义[J].山东医药,2007,47(22):84-84. 被引量:4
  • 9Paliga A,Onerheim R,Gologan A. EGFR and K-ras gene mutation status in squamous cell anal carcinoma:a role for concurrent radiation and EGFR inhibitors[J].British Journal of Cancer,2012,(11):1864-1868.
  • 10Goldstein NS,Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on cancer stage Ⅳ colon adenocarcinoma[J].Cancer,2001,(05):1331-1346.

二级参考文献54

  • 1徐晓辉,霍建民,车春利.非小细胞肺癌中MMP-9和EGFR的表达及对预后的意义[J].哈尔滨医科大学学报,2004,38(5):432-434. 被引量:3
  • 2王霞,陆嵘,房静远.激活细胞外信号调节激酶-丝裂原蛋白激酶信号通路对人结肠癌细胞增殖及相关基因的影响[J].中华医学杂志,2007,87(14):982-986. 被引量:4
  • 3[1]Weber JL,Dagmar K,Kalouse K,et al.Placental mossaicism and intrauterine survivival of trisomies 13 and 18[J].Am J hum Genet,1989,44:338.
  • 4[2]Thibodeau SN,Bren G,Schaid D.Microsatellite instability in cancer of the proximal colon[J].Science,1993,260:816.
  • 5[3]Aaltonen LA,Lauri A,Leach,et al.Clues to the pathogenesis of familial colorectal cancer[J].Science,1993,260:812.
  • 6[4]Ionov Y,Miguel A,Peinado,et al.Ubiquitous somatic mutations in simple repeated sequences reveal a new echanism for colon carcinogeesis[J].Nature,1993,363:558.
  • 7[5]Boyer JC,Umar A,Risinger JI,et al.Microsatellite instability mismatch repair beficiency and genetic defect in human cancer cell lines[J].Cancer Res,1995,(24):6063-6070.
  • 8[6]Risinger JI,Umar A,Boyer JC,et al.Microsatellite instabillty in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity[J].Cancer Res,1995,55(23):5664-5669.
  • 9[7]Keller G,Rudelius M,Vogelsang H,et al.Microsatellite instability and loss of heterozygosity in gastric carcinoma in comparion to family history[J].Cancer Res,1998,58:192.
  • 10[8]Lothe RA,Ragnhild A,Lauri A,et al.Genomice instability in colorectal cancor:Rclationship to clinicopathological variables and family history[J].Cancer Res,1993,53:5849.

共引文献23

同被引文献82

  • 1郑素洁.血清AFP联合CEA、CA19-9检测在原发性肝癌诊断中的临床评价[J].中国疗养医学,2011,20(8):746-746. 被引量:6
  • 2严茂林,陈和平,陈雨.1797例大肠癌患者临床及病理特点分析[J].中国药物经济学,2013,8(S3):195-196. 被引量:4
  • 3齐静,彭晖,顾振纶,梁中琴,杨纯正.伊马替尼耐药的K562细胞系的建立及其生物学特性研究[J].中华血液学杂志,2004,25(6):337-341. 被引量:20
  • 4赖琳,詹俊,李楚强,于钟,姚和瑞.大肠癌患者的临床、病理及预后分析576例[J].世界华人消化杂志,2007,15(9):1037-1040. 被引量:8
  • 5Sanchez-Font M, Sebastia J, Sanfeliu C, et al. Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, is underexpressed in Down syndrome fetal brains[J]. Cell Mol Life Sci, 2003, 60(7): 1513- 1523.
  • 6Wu X, Fu Z, Wang X. Peroxiredoxins in colorectal neoplasms[J]. Histol Histopathol, 2010, 25 (10): 1297-1303.
  • 7Neumann CA, Fang Q_. Are peroxiredoxins tumor suppressors [J] ? Curr Opin Pharmacol, 2007, 7(4): 375-380.
  • 8Kikuta K, Tochigi N, Saito S, et al. Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics[J]. Proteomics Clin Appl, 2010, 4(5): 560-567.
  • 9Kubota D, Mukaihara K, Yoshida A, et al. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma[J]. J Proteomics, 2013, 91 : 393-404.
  • 10Kalinina E, Berezov T, Chernov N, et al. Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance rormation[J]. Bull Exp Biol Med, 2012, 153(6): 878- 881.

引证文献6

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部